Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Authors not listed
National Institute of Mental Health (NIMH) · 2021
Abstract
Background:
About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.
Objective:
To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.
Eligibility:
Adults age 18 years and older in good general health who have an adult-onset neurodegenerative dementia, such as AD, FTD, corticobasal syndrome, Huntington s disease, or MCI, ALS and healthy adult volunteers enrolled in protocols 01-M-0254 or 17-M-0181.
Design:
Participants will be screened with medical history, physical exam with vital signs, and lab tests. They will have a neuropsychological testing. Their heart function will be measured.
Participants will have a magnetic resonance imaging (MRI) scan. The MRI scanner is a metal tube surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the tube. The machine makes noise. Participants will get earplugs.
Participants will have 2 PET scans. They will be injected with the study drugs through an intravenous catheter placed in an arm vein. The PET scanner is shaped like a doughnut. Participants will lie on a bed that slides in and out of the scanner. A plastic mask will be molded to their head to keep them from moving. A thin plastic tube will be put into an artery at the wrist or elbow crease area. This will be used to draw blood during the scan.
Participants will have 2-5 study visits. Participation lasts 1 week to 4 months, depending on scheduling.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Anonymous. (2021). Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease. <em>National Institute of Mental Health (NIMH)</em>. https://clinicaltrials.gov/study/NCT04396873
Vancouver
Anonymous. Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease. National Institute of Mental Health (NIMH). 2021.
BibTeX
@misc{anon2021PhaseS,
title = {Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease},
author = {Anonymous},
journal = {National Institute of Mental Health (NIMH)},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
National Institute of Mental Health (NIMH) 2008
Open access · US-GOV
Measurement of P-Glycoprotein Function in Alzheimer Disease, Parkinson Disease, and Frontotemporal Dementia Using Positron Emission Tomography
National Institute on Aging (NIA) 2026
Open access · US-GOV
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)
National Institute on Aging (NIA) 2024
Open access · US-GOV
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide
National Institute of Neurological Disorders and Stroke (NINDS) 2018
Open access · US-GOV
The Natural History of Blood-Brain Barrier Disruption in Stroke Patients With White Matter Hyperintensities (A Cohort Study)
National Institute of Neurological Disorders and Stroke (NINDS) 2006
Open access · US-GOV
MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems
National Eye Institute (NEI) 2012
Open access · US-GOV